Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Jon M Wigginton"'
Autor:
James L Gulley, Julie R Brahmer, Pedro J Romero, Francesco M Marincola, Charles G Drake, Stefani Spranger, Lisa H Butterfield, Douglas G McNeel, Alessandra Cesano, Thomas F Gajewski, Howard L Kaufman, Bernard A Fox, Leisha A Emens, Mario Sznol, Tanja D de Gruijl, Daniel S Chen, Patrick Hwu, Paolo Antonio Ascierto, Walter J Urba, Jon M Wigginton, Robert O Dillman, Michael B Atkins, Kim A Margolin, Paul M Sondel, Michael T Lotze, Ana Carrizosa Anderson, Ernest C Borden, David Kaufman, Michael J Mastrangelo, Marcela V Maus, David R Parkinson, George J Weiner, Jeffrey S Weber, F Stephen Hodi Jr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/0c91fa8ce43c41b59e024c5990dc73a7
Autor:
Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton, Lisa H. Butterfield
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-18 (2017)
Abstract As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic options that mobilize the immun
Externí odkaz:
https://doaj.org/article/dc8e8ba9ae4447e79a2e5ae3abfe1f76
Autor:
Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton, Peter P. Yu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-10 (2017)
Abstract As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a clinically beneficial alternativ
Externí odkaz:
https://doaj.org/article/57af0b0ce256407499283c283c70abc3
Autor:
Jedd D. Wolchok, Maria Jure-Kunkel, Taha Merghoub, Neal Rosen, Jon M. Wigginton, Ashok Gupta, Jianda Yuan, Shachi Vyas, Ruth Ann Gordon, Valerie Russell, Shigehisa Kitano, Jessica Katz, Charlotte Ariyan, Christine A. Pratilas, Gregg Masters, Margaret K. Callahan
PDF file - 528K, Supplementary Figure 1. BMS908662 enhances human T cell activation in vitro in a concentration-dependent manner. Supplementary Figure 2. BMS908662 inhibits the growth of BRAF mutant tumor cells in vitro. Supplementary Figure 3. BMS90
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d397f69a2a94ebf9bc0580eab85d3d
https://doi.org/10.1158/2326-6066.22537045.v1
https://doi.org/10.1158/2326-6066.22537045.v1
Autor:
Jedd D. Wolchok, Maria Jure-Kunkel, Taha Merghoub, Neal Rosen, Jon M. Wigginton, Ashok Gupta, Jianda Yuan, Shachi Vyas, Ruth Ann Gordon, Valerie Russell, Shigehisa Kitano, Jessica Katz, Charlotte Ariyan, Christine A. Pratilas, Gregg Masters, Margaret K. Callahan
RAF inhibitors selectively block extracellular signal–regulated kinase (ERK) signaling in BRAF-mutant melanomas and have defined a genotype-guided approach to care for this disease. RAF inhibitors have the opposite effect in BRAF wild-type tumor ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::347b0e505ed4a077c0e94936117300de
https://doi.org/10.1158/2326-6066.c.6548308.v1
https://doi.org/10.1158/2326-6066.c.6548308.v1
Autor:
Jon M. Wigginton, Fernanda I Arnaldez
Publikováno v:
Immuno Oncology Insights. 1:69-82
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::253f16a56bee1aa1bc014d8254e622ca
https://doi.org/10.18609/ioi.2020.008
https://doi.org/10.18609/ioi.2020.008
Autor:
Philip J. Gold, Jan K Davidson-Moncada, Keun-Wook Lee, Yeul Hong Kim, Jon M. Wigginton, Minori Koshiji Rosales, Se Hoon Park, Rosalyn A. Juergens, Haeseong Park, Hope E. Uronis, Cheng Ean Chee, Yee Chao, Daniel V.T. Catenacci, Aleksandra Franovic, Yoon-Koo Kang, Jeffrey L. Nordstrom, Kristen A. Marrone, Eun-Kee Song, Jill Lacy, Sunnie Kim, Johanna C. Bendell, Sang Cheul Oh, Matthew C.H. Ng, Ronan J. Kelly, Jennifer Yen, Jong Gwang Kim, Keith L. Knutson, Yung-Jue Bang, A. Craig Lockhart, Howard S. Hochster, Daner Li, Thierry Alcindor, Sun Jin Sym, Peter C. Enzinger
Publikováno v:
The Lancet Oncology. 21:1066-1076
Summary Background Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal antibody, is designed to more effectively potentiate innate immunity than trastuzumab. We aimed to evaluate the safety, tolerability, and antitumour activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2357b7a846f3a40ed58d8a051fe70a90
https://doi.org/10.1016/s1470-2045(20)30326-0
https://doi.org/10.1016/s1470-2045(20)30326-0
Autor:
Vincenzo Bronte, Vaios Karanikas, Marcus O. Butler, Lisa H. Butterfield, Brent A. Hanks, Jérôme Galon, Lance D. Miller, Isabelle Tanneau, Jon M. Wigginton, Samir N. Khleif, Dolores J. Schendel, John M. Kirkwood, Sacha Gnjatic, Mary L. Disis, Leif Håkansson, Laura Rosa Brunet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-18 (2017)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic options that mobilize the immune system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f937cd19bee5ddd8faf99f8d396b54dd
http://link.springer.com/article/10.1186/s40425-017-0243-4
http://link.springer.com/article/10.1186/s40425-017-0243-4
Autor:
Myles Clancy, Daniel Shao-Weng Tan, Danny Nguyen, David J. Witter, Ross A. Soo, Mark A. Socinski, Leigh Zawel, Helena Alexandra Yu, Jon M. Wigginton, Egbert F. Smit, James Chih-Hsin Yang, John Wrangle, Marianna Koczywas, Zofia Piotrowska, Vamsidhar Velcheti, Alexander I. Spira, Victor Ho-Fun Lee, Asher Page
Publikováno v:
Journal of Clinical Oncology. 39:9077-9077
9077 Background: NSCLC with EGFR ins20 represents a significant area of unmet need, with no approved targeted therapies. While several agents targeting EGFR ins20 are in development, wild-type (WT) EGFR-related adverse events (AEs) have been common a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91fcf6f85ce5535902e9743fd916fb9c
https://doi.org/10.1200/jco.2021.39.15_suppl.9077
https://doi.org/10.1200/jco.2021.39.15_suppl.9077